Celldex Therapeutics, Inc. (CLDX)
29.35
-0.25
(-0.84%)
USD |
NASDAQ |
Jun 10, 16:00
29.36
+0.01
(+0.03%)
After-Hours: 20:00
Celldex Therapeutics Gross Profit Margin (Quarterly) : -5.59K% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -5.59K% |
| December 31, 2025 | -574.4% |
| September 30, 2025 | |
| June 30, 2025 | -19.59% |
| March 31, 2025 | -24.75% |
| December 31, 2024 | 30.30% |
| September 30, 2024 | 75.37% |
| June 30, 2024 | 68.09% |
| March 31, 2024 | -396.8% |
| December 31, 2023 | 81.63% |
| September 30, 2023 | 49.44% |
| June 30, 2023 | -182.1% |
| March 31, 2023 | 24.92% |
| December 31, 2022 | 58.28% |
| September 30, 2022 | -64.86% |
| June 30, 2022 | -354.6% |
| March 31, 2022 | 0.00% |
| December 31, 2021 | -132.6% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| Date | Value |
|---|---|
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 38.58% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 40.62% |
| September 30, 2014 | 22.16% |
| June 30, 2014 | -41.22% |
| March 31, 2014 | -100.0% |
| December 31, 2013 | -23.06% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Insmed, Inc. | 83.82% |
| Kura Oncology, Inc. | 96.62% |
| Syndax Pharmaceuticals, Inc. | 95.93% |
| ACADIA Pharmaceuticals, Inc. | 90.75% |
| Alnylam Pharmaceuticals, Inc. | 81.91% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -48.24% |
| Return on Assets | -44.67% |
| Return on Invested Capital | -48.02% |
| Profit Margin (Quarterly) | -524.6K% |
| Operating Margin (Quarterly) | -562.9K% |
| Return on Net Operating Assets | -788.8% |